首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1714129篇
  免费   128040篇
  国内免费   3715篇
医药卫生   1845884篇
  2019年   13811篇
  2018年   20237篇
  2017年   15467篇
  2016年   16958篇
  2015年   19320篇
  2014年   26928篇
  2013年   39083篇
  2012年   54274篇
  2011年   57058篇
  2010年   33651篇
  2009年   31455篇
  2008年   52967篇
  2007年   56266篇
  2006年   56663篇
  2005年   53969篇
  2004年   52075篇
  2003年   49405篇
  2002年   47623篇
  2001年   92661篇
  2000年   94402篇
  1999年   77469篇
  1998年   19194篇
  1997年   16603篇
  1996年   16696篇
  1995年   16959篇
  1994年   15546篇
  1993年   14289篇
  1992年   58042篇
  1991年   55961篇
  1990年   53602篇
  1989年   51365篇
  1988年   46704篇
  1987年   45520篇
  1986年   42809篇
  1985年   40588篇
  1984年   29805篇
  1983年   25295篇
  1982年   14158篇
  1981年   12591篇
  1979年   25913篇
  1978年   17852篇
  1977年   15109篇
  1976年   14090篇
  1975年   14724篇
  1974年   17881篇
  1973年   17151篇
  1972年   15892篇
  1971年   14670篇
  1970年   13614篇
  1969年   12699篇
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
1.
2.
3.
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty.  相似文献   
4.
5.
Pharmaceutical Research - The quality testing and approval procedure for most pharmaceutical products is a streamlined process with standardized procedures for the determination of critical quality...  相似文献   
6.
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with intermediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozantinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment.  相似文献   
7.
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia...  相似文献   
8.
9.
10.
Journal of Pharmacokinetics and Pharmacodynamics - The integration between physiologically-based pharmacokinetics (PBPK) models and pharmacodynamics (PD) models makes it possible to describe the...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号